<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004649.pub2" GROUP_ID="COLOCA" ID="659603082510051992" MERGED_FROM="" MODIFIED="2008-08-05 11:15:43 +0200" MODIFIED_BY="Henning Keinke Andersen" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-08-05 11:14:36 +0200" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="049" REVMAN_SUB_VERSION="5.0.14" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-08-05 11:15:43 +0200" MODIFIED_BY="Henning Keinke Andersen">
<TITLE>Laxatives for the treatment of hemorrhoids.</TITLE>
<CONTACT>
<PERSON ID="62B6005E82E26AA200991D56D1FC64D0" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Pablo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Alonso-Coello</LAST_NAME>
<SUFFIX/>
<POSITION>Research fellow</POSITION>
<EMAIL_1>palonso@santpau.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Iberoamerican Cochrane Centre</ORGANISATION>
<ADDRESS_1>Hospital de la Santa Creu i Sant Pau</ADDRESS_1>
<ADDRESS_2>Sant Antoni Maria Claret 171 (Casa de Convalescencia)</ADDRESS_2>
<CITY>Barcelona</CITY>
<ZIP>08041</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 93 291 95 27</PHONE_1>
<PHONE_2/>
<FAX_1>+34 93 291 95 25</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-08-05 11:06:54 +0200" MODIFIED_BY="[Empty name]">
<PERSON ID="62B6005E82E26AA200991D56D1FC64D0" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Pablo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Alonso-Coello</LAST_NAME>
<SUFFIX/>
<POSITION>Research fellow</POSITION>
<EMAIL_1>palonso@santpau.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Iberoamerican Cochrane Centre</ORGANISATION>
<ADDRESS_1>Hospital de la Santa Creu i Sant Pau</ADDRESS_1>
<ADDRESS_2>Sant Antoni Maria Claret 171 (Casa de Convalescencia)</ADDRESS_2>
<CITY>Barcelona</CITY>
<ZIP>08041</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 93 291 95 27</PHONE_1>
<PHONE_2/>
<FAX_1>+34 93 291 95 25</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B52F088682E26AA20130726F3E7AFF2D" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Gordon</FIRST_NAME>
<MIDDLE_INITIALS>H</MIDDLE_INITIALS>
<LAST_NAME>Guyatt</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>guyatt@mcmaster.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Health Sciences Centre</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1>1200 Main Street West</ADDRESS_1>
<ADDRESS_2>Room 2C12</ADDRESS_2>
<CITY>Hamilton</CITY>
<ZIP>L8N 3Z5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 905 525 9140 ext: 22160</PHONE_1>
<PHONE_2/>
<FAX_1>+1 905 577 0017</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="65AC2C5582E26AA2011EF9F69EA83EB9" MODIFIED="2008-08-05 11:02:44 +0200" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Diane</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Heels-Ansdell</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Hamilton</CITY>
<ZIP>L8N</ZIP>
<REGION>ON</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12844" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>John</FIRST_NAME>
<MIDDLE_INITIALS>F</MIDDLE_INITIALS>
<LAST_NAME>Johanson</LAST_NAME>
<SUFFIX/>
<POSITION>Clinical Associate Professor of Medicine</POSITION>
<EMAIL_1>johnfj@uic.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>College of Medicine</DEPARTMENT>
<ORGANISATION>University of Illinois</ORGANISATION>
<ADDRESS_1>401 Roxbury Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rockford</CITY>
<ZIP>61107</ZIP>
<REGION>Illinois</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>815-397-7340</PHONE_1>
<PHONE_2/>
<FAX_1>815-397-2156</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12857" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maite</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lopez-Yarto</LAST_NAME>
<SUFFIX/>
<POSITION>Gynecologist (Senior House Officer)</POSITION>
<EMAIL_1>maitukaes@yahoo.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Obstetrics and Gynaecology</DEPARTMENT>
<ORGANISATION>Instituto Universitario Dexeus</ORGANISATION>
<ADDRESS_1>C/ del Pi 16 2º 1ª</ADDRESS_1>
<ADDRESS_2/>
<CITY>Barcelona</CITY>
<ZIP>08002</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>34 659 96 09 51</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="19890" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Ed</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mills</LAST_NAME>
<SUFFIX/>
<POSITION>Director of Research</POSITION>
<EMAIL_1>EMILLS@ccnm.edu</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Canadian College of Naturopathic Medicine</ORGANISATION>
<ADDRESS_1>1255 Sheppard Ave. East</ADDRESS_1>
<ADDRESS_2/>
<CITY>North York</CITY>
<ZIP>M2K 1E2</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 416-498-1255 ext: 324</PHONE_1>
<PHONE_2/>
<FAX_1>+1 416-498-1643</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="79BE612482E26AA2007D5B6E42FF02AC" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Qi</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Zhuo</LAST_NAME>
<SUFFIX>MSc</SUFFIX>
<POSITION/>
<EMAIL_1>dexterzq_83@163.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>West China Hospital</DEPARTMENT>
<ORGANISATION>Sichuan University</ORGANISATION>
<ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1>
<ADDRESS_2/>
<CITY>Chengdu</CITY>
<ZIP>610041</ZIP>
<REGION>Sichuan</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 28 13880626965</PHONE_1>
<PHONE_2/>
<FAX_1>+86 28 85422253</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-08-05 11:15:43 +0200" MODIFIED_BY="Henning Keinke Andersen" NOTES="&lt;p&gt;Minor update: 07/06/05&lt;/p&gt;" NOTES_MODIFIED="2008-08-05 11:09:20 +0200" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="1" MONTH="6" YEAR="2005"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="6" YEAR="2005"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="9" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2005"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="5" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="1" MONTH="6" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Centro Cochrane Iberoamericano (Barcelona)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Hospital de la Santa Creu i Sant Pau (Barcelona)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Instituto de Salud Carlos III. Subdirección General de Investigación Sanitaria, Ministerio de Sanidad y Consumo (Madrir)</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-05 11:09:36 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Laxatives for the treatment of hemorrhoids</TITLE>
<SUMMARY_BODY>
<P>Symptomatic hemorrhoids are a common medical condition but what causes them is not completely understood. Minimizing constipation with its associated prolonged straining may affect both lifestyle measures and medicines used as treatments for symptomatic hemorrhoids. <BR/>This systematic review suggests a beneficial effect of laxatives in the form of fiber for improving symptoms of hemorrhoids, especially bleeding. The improvement, halving the risk of having overall symptoms, was consistent over up to three months follow up. The results for other symptoms such as prolapse, pain or itching were not clear from the included trials. <BR/>The relatively small number of patients enrolled in trials to date could argue for the need for additional larger trials. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Symptomatic hemorrhoids are a common medical condition, which increase in prevalence in women during pregnancy and postpartum. Although the evidence appears to be inconclusive, narrative reviews and clinical practice guidelines recommend the use of laxatives (and fiber) for the treatment of hemorrhoids and relief of symptoms. This is due to their safety and low cost. <BR/> </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the impact of laxatives on a wide range of symptoms in people with symptomatic hemorrhoids. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Search strategy<BR/>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2005), MEDLINE (1966 to 2005), EMBASE (1980 to 2005), CINAHL (1982 to 2005), BIOSIS, and AMED (Allied and Alternative Medicine Database), for eligible trials (including conference proceedings). <BR/>We sought missing and additional information from authors, industry, and experts in the field.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We selected all published and unpublished randomised controlled trials that compared any type of laxative to placebo or no therapy in any patient population. <BR/> </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently screened studies for inclusion and retrieved all potentially relevant studies. Data were extracted from studies that met our selection criteria on study population, intervention used, pre-specified outcomes, and methodology. We extracted methodological information for the assessment of internal validity: existence and method of generation of the randomization schedule, and method of allocation concealment; blinding of caregivers and outcomes assessors; numbers of and reasons for participants lost to follow up; and use of validated outcome measures. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Seven randomised trials enrolling a total of 378 participants to fiber or a non-fiber control were identified. Meta-analyses using random-effects models showed that laxatives in the form of fiber had a beneficial effect in the treatment of symptomatic hemorrhoids. The risk of not improving hemorrhoids and having persisting symptoms decreased by 53% in the fiber group (risk reduction (RR) 0.47, 95% CI 0.32 to 0.68). These results are compatible with large treatment effects regarding prolapse, pain, itching, although the pooled analyses showed a tendency toward no-effect for these parametres. <BR/>The effect on bleeding showed a significant difference in favour of the fiber (RR 0.50, 95% CI 0.28 to 0.89). <BR/>Studies including data on multiple follow ups (usually after six weeks and three months) showed consistent results over time. <BR/>However, we have to stress two possible limitations of this review: the risk of publication bias, and only moderate study quality. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The use of fiber shows a consistent beneficial effect for relieving overall symptoms and bleeding in the treatment of symptomatic hemorrhoids. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Hemorrhoidal tissue is a normal anatomic structure located in the anal canal that plays a role in differentiating between liquids, solids, and gas and maintaining anal continence (<LINK REF="REF-Beck-1998" TYPE="REFERENCE">Beck 1998</LINK>). Hemorrhoids are considered a medical condition only if symptomatic. The dentate line divides the hemorrhoidal tissue into internal and external hemorrhoids. Internal hemorrhoids are classically divided into four categories depending on the degree of any prolapse (I to IV). Recently it has been suggested that it is more appropriate to classify internal hemorrhoids on the basis of presence or absence of bleeding or prolapse (<LINK REF="REF-Abcarian-1994" TYPE="REFERENCE">Abcarian 1994</LINK>). <BR/>Symptomatic hemorrhoids are a common medical condition with a prevalence ranging from 4.4% in the general population to 36.4% in general practice (<LINK REF="REF-Abramowitz-2001" TYPE="REFERENCE">Abramowitz 2001</LINK>). It has been reported that one in three persons with symptomatic hemorrhoids seek medical help (<LINK REF="REF-Johanson-1990" TYPE="REFERENCE">Johanson 1990</LINK>). Women have an increased prevalence during pregnancy and in the postpartum period (<LINK REF="REF-Beck-1998" TYPE="REFERENCE">Beck 1998</LINK>). However, the pathophysiology is not completely understood other than that structural and vascular changes are involved (<LINK REF="REF-Beck-1998" TYPE="REFERENCE">Beck 1998</LINK>); chronic straining is inconsistently associated with symptomatic hemorrhoids (<LINK REF="REF-Johanson-1990" TYPE="REFERENCE">Johanson 1990</LINK>). <BR/>Symptomatic hemorrhoids are generally considered a benign condition but can be bothersome for some patients. Bleeding and prolapse represent the most common symptoms but patients may also experience discomfort, pain, and soiling or mucous discharge associated with local irritation and itching. Internal hemorrhoids are usually painless and it is any bleeding or prolapse that takes a person to the physician. Bleeding is usually described as bright red spotting on toilet tissue, or dripping in the toilet bowl and occurs at the end of defecation, separate from the stool. External hemorrhoids can be asymptomatic or associated with discomfort and acute pain in the case of a local thrombosis. All these symptoms are, however, not specific for hemorrhoids and a diagnosis requires clinical examination: anorectal examination, digital palpation, and anoscopy or colonoscopy in some cases (<LINK REF="REF-Alonso_x002d_Coello-2003" TYPE="REFERENCE">Alonso-Coello 2003</LINK>). <BR/>The decision whether or not to treat hemorrhoids depends on the frequency and severity of symptoms. The initial approach usually takes place in primary care and for most people this is the only treatment they need (Grades I to II). Traditional conservative treatment to relieve symptoms includes increasing the amount of fiber and water intake in the diet, fiber supplements, and topical therapies (steroids, anesthetics). Some people may benefit from avoiding certain foods or from a short course of venotonics (such as flavonoids). </P>
<P>Clinicians may recommend either non-surgical treatment (for example rubber band ligation) or surgical interventions (hemorrhoidectomy) in people who do not improve with the initial treatments, or in people with a more significant degree of prolapse (grades III to IV) (<LINK REF="REF-Abramowitz-2001" TYPE="REFERENCE">Abramowitz 2001</LINK>; <LINK REF="REF-Brisinda-2000" TYPE="REFERENCE">Brisinda 2000</LINK>). These procedures fix the sliding hemorrhoidal tissue back onto the muscle wall of the anal canal. Tissue fibrosis (for example sclerotherapy, or infrared coagulation), or tissue destruction with subsequent fibrosis (as with hemorrhoidectomy) can achieve tissue fixation (<LINK REF="REF-Johanson-1992" TYPE="REFERENCE">Johanson 1992</LINK>). Only about 10% of people require surgical treatment (hemorrhoidectomy) either due to the severity of the disease or failure of conservative measures (<LINK REF="REF-Bleday-1992" TYPE="REFERENCE">Bleday 1992</LINK>). <BR/>To minimize constipation, and the prolonged straining that may be associated with it, is one of the main purposes of lifestyle measures and medical treatment. The initial approach is to increase the amount of water and fiber in the diet, or to introduce a laxative. Constipation may be due to low fluid intake (<LINK REF="REF-Petticrew-2001" TYPE="REFERENCE">Petticrew 2001</LINK>) but the effectiveness of increasing fluid intake as a treatment for constipation remains unknown. Dietary fiber intake has been positively associated with increases in bowel movement frequency and fecal mass among individuals with occasional or mild constipation (<LINK REF="REF-Bennett-1996" TYPE="REFERENCE">Bennett 1996</LINK>; <LINK REF="REF-Spiller-1994" TYPE="REFERENCE">Spiller 1994</LINK>). In randomised trials other types of laxatives (stimulant laxatives, osmotic agents, and fecal softeners) have shown some effectiveness for the treatment of constipation (<LINK REF="REF-Jones-2002" TYPE="REFERENCE">Jones 2002</LINK>; <LINK REF="REF-Kenny-2001" TYPE="REFERENCE">Kenny 2001</LINK>; <LINK REF="REF-Petticrew-2001" TYPE="REFERENCE">Petticrew 2001</LINK>; <LINK REF="REF-Tramonte-1997" TYPE="REFERENCE">Tramonte 1997</LINK>) but poor study methodology has not allowed clear evidence. <BR/>Several small clinical trials have evaluated the effect of fiber compared with placebo in people with hemorrhoids (<LINK REF="STD-Moesgaard-1982" TYPE="STUDY">Moesgaard 1982</LINK>; <LINK REF="STD-Perez_x002d_Miranda-1996" TYPE="STUDY">Perez-Miranda 1996</LINK>). Authors of narrative reviews (<LINK REF="REF-Johanson-2002" TYPE="REFERENCE">Johanson 2002</LINK>; <LINK REF="REF-Johanson-2002a" TYPE="REFERENCE">Johanson 2002a</LINK>) and clinical practice guidelines (<LINK REF="REF-Alonso-2002" TYPE="REFERENCE">Alonso 2002</LINK>; <LINK REF="REF-Madoff-2004" TYPE="REFERENCE">Madoff 2004</LINK>) have found the evidence inconclusive but overall recommend the use of fiber due to its safety and low cost (<LINK REF="REF-Johanson-2002a" TYPE="REFERENCE">Johanson 2002a</LINK>). <BR/>We have conducted a systematic review of the impact of laxatives on a wide range of symptoms in people with symptomatic hemorrhoids in order to establish the strength of the available evidence. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the efficacy of laxatives for the treatment of symptomatic hemorrhoids.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>We considered published as well as unpublished randomised controlled trials that compared any type of laxative to placebo or no therapy. We also considered crossover trials and quasi-randomised methods of treatment allocation. There were no language restrictions.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>1) People of both gender and all ages with symptomatic hemorrhoids<BR/>2) Pregnant women or women after delivery with symptomatic hemorrhoids</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Any kind of laxative compared to placebo or no therapy.<BR/>Laxatives included:<BR/>1. fiber administered orally, where fiber included<BR/> - a high fiber diet, or<BR/> - bulking agents such as bran, ispaghula, psyllium<BR/>3. stimulant laxatives, for example senna and bisacodyl<BR/>4. faecal softeners, such as liquid paraffin, seed oils<BR/>5. osmotic agents, such as lactulose, magnesium hydroxide, sorbitol, and lactitol</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Any of the following outcomes as recorded in a study: <BR/>- individual or global symptom improvement; <BR/>-number of recurrences in a time period; <BR/>-change in the degree of prolapse; <BR/>-need for surgical treatment;<BR/>-adverse effects. <BR/>We contacted authors to obtain additional data and details about the key validity methods. </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2005), the OVID versions of MEDLINE (1966 to April Week 2 2005), EMBASE (1980 to 2005, week 17), CINAHL (Cumulative Index to Nursing &amp; Allied Health Literature) (1982 to April Week 4 2005), limiting our searches to randomised controlled trials using the Cochrane highly sensitive search strategy (Appendix 1) (<LINK REF="REF-Dickersin-2002" TYPE="REFERENCE">Dickersin 2002</LINK>). <BR/>We modified the searches for the databases CENTRAL, BIOSIS, and AMED (Allied and Alternative Medicine Database), also including conference proceedings. The contact author (PA) can provide the full details of search strategies. The authors screened reference lists from all retrieved articles, and from reviews and clinical practice guidelines (<LINK REF="REF-Alonso-2002" TYPE="REFERENCE">Alonso 2002</LINK>; <LINK REF="REF-Johanson-2002" TYPE="REFERENCE">Johanson 2002</LINK>; <LINK REF="REF-Johanson-2002a" TYPE="REFERENCE">Johanson 2002a</LINK>; <LINK REF="REF-Madoff-2004" TYPE="REFERENCE">Madoff 2004</LINK>) to identify additional studies. Furthermore, we sought additional trials from pharmaceutical companies and experts in the field. Finally, we searched for on-going trials in the Meta Register of Controlled Trials (mRCT), US NIH register, and the Register of the Center for Clinical Trials and Evidence-Based Healthcare. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Data abstraction<BR/>Two authors (EM, PA) independently screened identified studies for inclusion, and extracted data on study population, intervention, pre-specified outcomes, and methodology from included trials. In both phases, we resolved disagreements by consensus between authors, if unsolved after contacting study authors for further information. We used Cohen's kappa to assess agreement between the two authors on the selection of articles for inclusion (<LINK REF="REF-Fleiss-1973" TYPE="REFERENCE">Fleiss 1973</LINK>).</P>
<P>Validity assessment<BR/>We extracted methodological information for the assessment of internal validity (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>): existence and method of generation of the randomization schedule, and method of allocation concealment (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>); blinding of caregivers and outcomes assessors; number and reasons of patients lost to follow-up; and use of validated outcome measures. </P>
<P>Quantitative data synthesis<BR/>Trials did not consistently use the same symptom measures; all of them, however, recorded the proportion of patients either free of symptoms, with symptom improvement, or still symptomatic. We considered the outcomes patients free of symptoms and patients with symptomatic improvement as equivalent, and pooled each outcome of interest based on the a priori expectation of a similar magnitude and direction of treatment effect. </P>
<P>Results were presented as the relative risk of being symptomatic and not having improved. We also calculated pooled risk differences for being symptomatic or persisting symptoms for the different outcomes. There was a pronounced heterogeneity in the trial reports on duration of follow-up, the number of discrete measurements they made, and the timing of their first follow -up measurement. Investigators' first measurement of follow-up varied from six weeks to three months - which was used for all our pooled analyses. In studies with multiple follow -ups we compared the different estimates across each study for consistency. We also included the pooled relative risks of re-treatment, patient satisfaction, need for additional treatment, and adverse effects. </P>
<P>We undertook the analysis using the intention-to-treat principle, including all patients in the study arm to which they were originally allocated, as opposed to only those symptomatic at the start of a study. We used Review Manager 4.2 (The Cochrane Collaboration, Oxford, UK) to aggregate data for each outcome using a random effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) We presented all pooled effect estimates with 95% confidence intervals (CI); and all P values were two sided. </P>
<P>In crossover studies, we analysed the data in the same way as for parallel group studies, by comparing treatment periods to control periods. This analysis was conservative both because it ignored the decrease in variance associated with the pairing, and because any carry-over would have reduced the magnitude of effect. We tested for between-study heterogeneity for each pooled comparison using the Cochrane Q statistic. We also reported the I<SUP>2</SUP> statistic, which is the proportion of total variation among studies that is likely to be explained by between-study heterogeneity rather than by chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Irrespective of the results of the formal statistical test of heterogeneity we tested whether our a priori hypotheses could explain variability in the magnitude of treatment effects across studies. For each hypothesis, we tested the difference in estimates of treatment effect between the two subgroups using a Z test and considered P value&lt;0.05 to be statistically significant (<LINK REF="REF-Fleiss-1993" TYPE="REFERENCE">Fleiss 1993</LINK>)</P>
<P>Our a priori hypotheses to explain heterogeneity were: (1) severity: smaller treatment effect in hemorrhoids grade III to IV compared to grade I to II; (2) condition: smaller treatment effect in thrombosed hemorrhoids versus non-thrombosed; (3) intervention: smaller treatment effect in studies that used another treatment for hemorrhoids in both treatment arms (for example venotonic in both arms comparing fiber versus no fiber or placebo) (4) methodology: smaller treatment effect in studies with adequate allocation concealment in studies with appropriate blinding of caregivers and smaller treatment effect in cross-over compared to parallel trials. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>We excluded four identified studies for the following reasons: partial duplicate publication (<LINK REF="STD-Hunt-1981a" TYPE="STUDY">Hunt 1981a</LINK>, Maté1996), wrong topic or retrospective study (<LINK REF="STD-Gorgul-1999" TYPE="STUDY">Gorgul 1999</LINK>). <BR/>Three studies were abstracts, of which two were published later also as full text (<LINK REF="STD-Hunt-1981a" TYPE="STUDY">Hunt 1981a</LINK>, Maté1996) - and subsequently included, whereas the trial by Craven was an abstract and apparently never published as a full article (<LINK REF="STD-Craven-1976" TYPE="STUDY">Craven 1976</LINK>).<BR/>
<B>
<BR/>Type of studies</B>
<BR/>Seven studies comparing fiber versus placebo met the eligibility criteria (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Six used a parallel group and one a cross-over design (<LINK REF="STD-Webster-1978" TYPE="STUDY">Webster 1978</LINK>).</P>
<P>
<B>Participants</B>
<BR/>All trials included adults with symptomatic hemorrhoids (grades I to III) and most patients presented with rectal bleeding as their main complaint. Mean age for the populations studied was approximately 40 years of age (range 23 to 71). Sample sizes varied between 28 and 92 with a mean of around 50 patients. We did not locate any studies with thrombosed hemorrhoids or with a focus on pregnant women.</P>
<P>
<B>Interventions</B>
<BR/>All articles comparing laxatives evaluated the use of fiber versus placebo. We did not identify any studies using other types of laxatives. The types of fiber studied were Ispaghula husk (three trials), plantago ovata or psyllium (two trials), sterculia (one trial) and unprocessed bran (one trial). </P>
<P>
<B>Outcomes</B>
<BR/>Most trials assessed the degree of improvement of individual (bleeding, pain, itching, and prolapse) or overall symptoms, by patient. Some of the studies used categorical scales (for example no symptoms, better, same, or worse) (<LINK REF="STD-Broader-1974" TYPE="STUDY">Broader 1974</LINK>; <LINK REF="STD-Moesgaard-1982" TYPE="STUDY">Moesgaard 1982</LINK>; <LINK REF="STD-Webster-1978" TYPE="STUDY">Webster 1978</LINK>), others used a visual analogue scale (VAS) (<LINK REF="STD-Jensen-1988" TYPE="STUDY">Jensen 1988</LINK>), or, as in the case of the included abstracts, did not describe the outcome measures (<LINK REF="STD-Foster-1979" TYPE="STUDY">Foster 1979</LINK>; <LINK REF="STD-Hunt-1981" TYPE="STUDY">Hunt 1981</LINK>). Some studies provided absolute numbers by dichotomizing the results and presenting the number of patients who were symptom free, or lumping patients with 'no symptoms' or 'better' together (<LINK REF="STD-Moesgaard-1982" TYPE="STUDY">Moesgaard 1982</LINK>); while others provided the average number of bleeding episodes for a certain time period (<LINK REF="STD-Perez_x002d_Miranda-1996" TYPE="STUDY">Perez-Miranda 1996</LINK>). <BR/>In the first RCT describing the use of fiber for hemorrhoids, Broader et al. randomised 40 unselected outpatients who had internal hemorrhoids with anal bleeding, prolapse, or discomfort to a bulk-forming agent (sterculia) or a non-bulk forming placebo (starch) (<LINK REF="STD-Broader-1974" TYPE="STUDY">Broader 1974</LINK>). Treatment duration was three months and symptom assessment was performed every month. The outcomes included single symptom improvement (bleeding, prolapse, or discomfort) measured monthly or patient's overall impression. <BR/>Webster et al used a crossover design to evaluate the effect of ispaghula versus placebo and randomized 67 patients to two six-week treatment periods. There was no reporting of a washout period (<LINK REF="STD-Webster-1978" TYPE="STUDY">Webster 1978</LINK>). Participants comprised those who were referred to an outpatient surgery clinic with symptomatic hemorrhoids (Grades I to III) and 43% of them had had their symptoms for more than a year. Concomitant laxatives were allowed. Outcome assessment took place at six and 12 weeks and included: individual symptoms and overall improvement (better, same or worse), laxative use, ease of defecation, bowel habit, and palatability of the intervention. Six patients (11%) complained of constipation on admission to the trial. <BR/>Moesgaard et al. randomised 52 patients,with grades I to III hemorrhoids to psyllium seed dietary fiber versus placebo (12% patients with constipation at baseline) (<LINK REF="STD-Moesgaard-1982" TYPE="STUDY">Moesgaard 1982</LINK>). Treatment duration was six weeks. Symptoms (bleeding; pain at defecation; a composite of pruritus, anal secretion, and prolapse) and endoscopic assessment took place at three and six weeks. Patient overall assessment was a composite of the patients with 'no symptoms' or feeling 'better' compared with the remainder of patients ('same' or 'worse'). <BR/>Perez-Miranda et al randomised 50 consecutive patients with bleeding hemorrhoids to a preparation of plantago ovata or placebo (vitamin B preparation) taken over 15 days (<LINK REF="STD-Perez_x002d_Miranda-1996" TYPE="STUDY">Perez-Miranda 1996</LINK>). The investigators assessed the number of rectal bleeding episodes at 15, 30 and 45 days. During anoscopy, they assessed: the degree of prolapse, presence of hemorrhoids bleeding on contact, and the number of congested haemorrhoidal cushions. They also assessed the degree of prolapse as the patient performed a Valsalva manoeuvre. <BR/>Foster et al published a study, only available as an abstract, where they randomised 41 patients to ispaghula or a matching placebo. Evaluation of overall symptom improvement and anal and rectal pressure took place after one month of treatment (<LINK REF="STD-Foster-1979" TYPE="STUDY">Foster 1979</LINK>). This was the only trial in which authors failed to respond to our request for clarification and additional information. <BR/>Hunt et al randomised 28 patients with bleeding hemorrhoids (grade I to II degree) to six weeks of treatment with ispaghula Husk or placebo (<LINK REF="STD-Hunt-1981" TYPE="STUDY">Hunt 1981</LINK>). The study was published originally as an abstract (<LINK REF="STD-Hunt-1981a" TYPE="STUDY">Hunt 1981a</LINK>) and later the same year as a letter by the same authors. One of the origional authors was unable to provide any additional data. The outcomes assessed were: number of patients with rectal bleeding, severity of hemorrhoids, and ease of defecation. Sixty eight per cent of patients presented with constipation at baseline. <BR/>Jensen et al studied a different population from the rest of the studies (<LINK REF="STD-Jensen-1988" TYPE="STUDY">Jensen 1988</LINK>). The authors randomized 92 patients with third-degree hemorrhoids (grade III) to rubber band ligation (RBL) plus bran versus RBL alone and followed patients for 18 months. An independent observer assessed patients every six months using a visual analogue scale (0 to 10, where 0 meant no symptoms and 10 severe symptoms). Authors considered the number of rubber band ligations until disappearance of symptoms, recurrent symptoms (by individual symptoms and global number), and adverse effects as the main outcomes</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The reported quality was generally low with very little detail provided concerning key validity methodologies such as allocation concealment. When contacted directly the majority of authors provided additional information that generally indicated they had met methodological criteria. This finding is in agreement with recent data suggesting authors typically use concealment of randomisation and blinding despite the failure to report these methods (<LINK REF="REF-Devereaux-2004" TYPE="REFERENCE">Devereaux 2004</LINK>). None of the included studies used validated questionnaires to assess study outcomes.</P>
<P>
<B>Randomisation and allocation concealment</B>
<BR/>Most studies provided additional information about the generation and method of randomisation. Four out of seven used an adequate method of allocation concealment, one was inadequate and two did not provide any information.</P>
<P>
<B>Blinding</B>
<BR/>Five studies used the term 'double blind'. Out of these five, four of them reported or informed us about the level of blinding. In three trials, both patients and data collectors were blinded and in another one data collectors and analysts (<LINK REF="STD-Perez_x002d_Miranda-1996" TYPE="STUDY">Perez-Miranda 1996</LINK>). One trial reported the use of an independent observer but did not report blinding status of the rest of the participants (<LINK REF="STD-Jensen-1988" TYPE="STUDY">Jensen 1988</LINK>).<BR/>
<B>
<BR/>Loss to follow up </B>
<BR/>Four studies out of the seven provided appropriate detail of the patients lost to follow up (range 2% to 21%) </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>The two review authors achieved good agreement in the initial selection of trials for inclusion from the titles (k = 0.67, 95% CI 0.48 to 0.85) and excellent agreement on the final stage of inclusion from full-text articles (k = 1.0). Six out of the seven authors responded positively to our request for additional information regarding key validity issues and provided it. In studies that measured symptoms on more than one visit, usually at six weeks and at three months,the results for later time points were very similar to earlier time points. We did not observe significant heterogeneity in our comparisons for the overall assessment but I2 ranged from 1.1% to 45.6% (substantial heterogeneity exists when I2 exceeds 50%). None of our a priori hypotheses explained the variability in results between the studies. Crossover estimates for the different outcomes were consistently closer to one than the parallel group estimates, suggesting a potential carryover effect that decreased the size of the estimate. </P>
<P>
<B>Overall assessment</B>
<BR/>The pooled analysis for overall improvement showed a 53% reduction in the risk of not improving or not being asymptomatic (RR 0.47, 95% CI 0.32 to 0.68) (<LINK REF="STD-Broader-1974" TYPE="STUDY">Broader 1974</LINK>; <LINK REF="STD-Foster-1979" TYPE="STUDY">Foster 1979</LINK>; <LINK REF="STD-Hunt-1981" TYPE="STUDY">Hunt 1981</LINK>; <LINK REF="STD-Moesgaard-1982" TYPE="STUDY">Moesgaard 1982</LINK>; <LINK REF="STD-Webster-1978" TYPE="STUDY">Webster 1978</LINK>). Results were consistent across studies (heterogeneity P value 0.40, I2 1.1%). The pooled risk difference for being symptomatic or having persisting symptoms for the overall assessment was -24% (95% CI -0.37 to -0.12). The range of absolute percentages between trials for those not improved was 0.16 to 0.40 for fiber versus 0.23 to 0.61 for placebo. </P>
<P>
<B>Bleeding<BR/>
</B>Four studies that compared fiber to placebo reported bleeding as an individual outcome (<LINK REF="STD-Broader-1974" TYPE="STUDY">Broader 1974</LINK>; <LINK REF="STD-Hunt-1981" TYPE="STUDY">Hunt 1981</LINK>; <LINK REF="STD-Moesgaard-1982" TYPE="STUDY">Moesgaard 1982</LINK>; <LINK REF="STD-Webster-1978" TYPE="STUDY">Webster 1978</LINK>). All results showed either a trend or a significant difference in favour of the fiber group. The pooled analysis showed a 50% relative risk reduction in the active treatment arm (RR 0.50, 95% CI 0.28 to 0.89) No statistically significant heterogeneity was present but I2 was moderate (P value 0.14, I2 45.6%) Pooled risk difference for being symptomatic and having persisting symptoms of bleeding was -0.26 (95% CI -0.44 to -0.07). The range of absolute percentages between trials of those being symptomatic or having persisting symptoms was 0.07 to 0.31 for fiber versus 0.38 to 0.76 for placebo. <BR/>One of the included studies provided the number of bleeding episodes: during the first 15 days, from day 15 to 30, and from 30 to 45 days. These data could not be pooled with the rest of the studies as the authors no longer had access to the raw data (<LINK REF="STD-Perez_x002d_Miranda-1996" TYPE="STUDY">Perez-Miranda 1996</LINK>). This study demonstrated a significant benefit in the treatment group compared to placebo but only in the last two periods (5.5 +/- 3.2 bleeding episodes versus 3.1 +/- 2.7 and 5.5+/- 2.9 versus 1.1 +/- 1.4, respectively). There was no significant difference in the number of patients with hemorrhoids bleeding on contact, using an anoscope or finger (RR 0.13, 95% CI 0.01 to 2.29) (<LINK REF="STD-Perez_x002d_Miranda-1996" TYPE="STUDY">Perez-Miranda 1996</LINK>). </P>
<P>
<B>Prolapse</B>
<BR/>The pooled analysis of the studies showed a non-significant difference between treatment and placebo for persistent prolapse (RR 0.79, 95% CI 0.37 to 1.67) (<LINK REF="STD-Broader-1974" TYPE="STUDY">Broader 1974</LINK>; <LINK REF="STD-Moesgaard-1982" TYPE="STUDY">Moesgaard 1982</LINK>; <LINK REF="STD-Webster-1978" TYPE="STUDY">Webster 1978</LINK>). The pooled risk difference for being symptomatic or having persisting symptoms of prolapse was -0.08 (95% CI -0.22 to -0.06). The range of absolute percentages between trials of those not improved was 0.03 to 0.35 for fiber versus 0.22 to 0.35 for placebo. No statistically significant heterogeneity was present but I2 was moderate (P value 0.21, I2 35.7%). Perez-Miranda et al likewise reported no differences in the degree of prolapse compared with baseline, by hemorrhoidal grade (<LINK REF="STD-Perez_x002d_Miranda-1996" TYPE="STUDY">Perez-Miranda 1996</LINK>). <BR/>
<B>
<BR/>Pain<BR/>
</B>We pooled together two studies evaluating pain or discomfort (<LINK REF="STD-Broader-1974" TYPE="STUDY">Broader 1974</LINK>; <LINK REF="STD-Moesgaard-1982" TYPE="STUDY">Moesgaard 1982</LINK>). The pooled estimate showed a non significant trend in favour of fiber (RR=0.33, 95% CI 0.07 to 1.65). No statistically significant heterogeneity was present but I<SUP>2</SUP> was moderate (P value = 0.14, I<SUP>2 </SUP>=53%) </P>
<P>
<B>Itching</B>
<BR/>The two studies that evaluated itching did not find a significant difference between the groups (RR 0.71, 95% CI 0.24 to 2.10) (<LINK REF="STD-Moesgaard-1982" TYPE="STUDY">Moesgaard 1982</LINK>; <LINK REF="STD-Webster-1978" TYPE="STUDY">Webster 1978</LINK>). One of the studies evaluated a composite outcome with itching and anal secretion but authors could not provide the data for the individualcomponents (<LINK REF="STD-Moesgaard-1982" TYPE="STUDY">Moesgaard 1982</LINK>). No statistically significant heterogeneity was present but I2 was moderate (P value 0.21, I2 36.4%). The range of absolute percentages between trials of those being symptomatic or having persisting symptoms was 0.03 to 0.40 for fiber versus 0.16 to 0.43 for placebo. </P>
<P>
<B>Recurrences or need for further treatment</B>
<BR/>Only one study comparing fiber with placebo looked at the number of recurrences in the long term (<LINK REF="STD-Jensen-1988" TYPE="STUDY">Jensen 1988</LINK>). Jensen et al. reported less overall recurrence in the fiber group (15% versus 45%) at 18 months in patients with third degree hemorrhoids after rubber band ligation (RR 0.34, 95%CI 0.15, 0.77) During the follow-up period there were fewer recurrent protrusions in the treatment group (10%vs 38%) In the same study the number of rubber band ligations required until disappearance of symptoms was lower in the fiber group (median 2, range 1 to 4 versus 3, range 1 to 5)</P>
<P>
<B>Adverse effects</B>
<BR/>The most common adverse effects with fiber consisted of gastrointestinal symptoms, typically starting at the beginning of the study, and were generally not severe enough for participants to stop taking the treatment. Adverse effects were inconsistent with some studies reporting a 50% incidence of bloating, the most common complaint, in the treatment group versus none in the placebo group (<LINK REF="STD-Jensen-1988" TYPE="STUDY">Jensen 1988</LINK>). Two of the studies did not observe any adverse effects (information provided by authors) (<LINK REF="STD-Hunt-1981" TYPE="STUDY">Hunt 1981</LINK>; <LINK REF="STD-Moesgaard-1982" TYPE="STUDY">Moesgaard 1982</LINK>)</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>In this systematic review we found that fiber had a beneficial effect in the treatment of symptomatic hemorrhoids. The risk of not improving or having persisting symptoms decreased by 53% in the fiber group (RR 0.47, 95% CI 0.32 to 0.68) and the risk of bleeding showed a significant difference in favour of fiber (RR 0.50, 95% CI 0.28 to 0.89). We also found that in studies with multiple follow ups, usually at six weeks and at three months, the results for later time points were very similar to earlier time points. Results are also compatible with large treatment effects in prolapse, pain, itching, but even in the pooled analyses confidence intervals were wide and compatible with no effect (RR=0.79, 95% CI 0.37 to 1.67; RR=0.33, 95% CI 0.07 to 1.65; and RR=0.71, 95% CI 0.24 to 2.10 respectively). Results showed a non-significant trend toward increases in mild adverse events in the fiber group (RR=6.0, 95% CI 0.57 to 64.8). </P>
<P>One of the few outcomes that failed to show a relative improvement with fiber was the degree of prolapse. This is not surprising as prolapse, as opposed to bleeding or itching, involves a structural change that is unlikely to improve with a change in the consistency of feces or the frequency of defecation. In other words, damage to the connective tissue that supports the hemorrhoidal cushions resulting from chronic straining is not likely to improve with fiber supplementation alone. </P>
<P>Fiber is generally used in patients suffering from first and second-degree hemorrhoids, that is those with a lesser component of prolapse. Most trials evaluated grade I to II hemorrhoids, and the studies that included mixed populations failed to provide data according to grade of severity. While fiber might also be effective in people with more advanced stages of hemorrhoidal disease, this remains largely unaddressed. </P>
<P>Moderate study quality and publication bias are potential limitations to this systematic review. We contacted authors and were given access to the methodology for the majority of trials, which improved the quality in comparison to the published articles. We found too few trials for the funnel plot to be of use and the small number and size of the trials raises the serious possibility of publication bias. On the other hand, our efforts to locate unpublished studies by contacting authors, experts and the pharmaceutical industry and our success, we located two previously unpublished abstracts, make serious publication bias less likely. To the extent that we failed to identify additional unpublished studies with small or absent treatment effects our results may represent an overestimate of the true underlying effect of treatment. We believe, however, that the limitations outlined above are relatively minor and that the inferences drawn are moderately strong. In summary, fiber shows a consistent beneficial effect for overall symptoms as well as bleeding in the treatment of symptomatic hemorrhoids. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Fiber seems an effective treatment for symptomatic hemorrhoids, measuring overall symptom improvement and bleeding. Weaknesses are relatively minor (moderate study quality, use of unvalidated symptom ratings, and risk of publication bias), and inferences are therefore moderately strong.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Future trials should explore head-to-head comparisons with common first line treatments like venotonics (for example flavonoids) or topical treatments (local anesthetics and/or steroids). Addressing prevention of recurrences over the long term would also be of use. The consistent use of a small number of validated scales in future trials would facilitate comparisons and increase the validity of the results. <BR/>In future trials it is recommendable that randomisation should be concealed, and followed by an analysis that adheres to the principle of intention to treat; participants, caregivers, and those administering questionnaires and analyzing data must blind to allocation; and investigators must use validated questionnaires addressing patients' symptoms. Ideally, investigators in this area will adopt single rigorously-designed and validated questionnaires (or a single questionnaire) that addressed each symptom complex. Such questionnaires are likely to work best using seven-point scales as response options. In addition, each investigation shoudl report the number of patients bleeding or not bleeding at the time of each assessment, the number of bleeding episodes in eacj time period, and the duration of each bleeding episode. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The work of Dr Alonso-Coello is partly funded by grant 01/F070 of the Instituto de Salud Carlos III, Subdirección General de Investigación Sanitaria and by the Spanish Society of Family Practice (semFYC). Dr. Alonso-Coello is a PhD candidate at the Pediatrics, Obstetrics and Gynecology, and Preventive Medicine Department (Universidad Autónoma de Barcelona, España). <BR/>We would like to thank all the authors of the studies included in the review that provided information about their trials.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-08-05 11:09:36 +0200" MODIFIED_BY="[Empty name]">
<P>None mentioned</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-05 11:10:20 +0200" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Broader-1974" NAME="Broader 1974" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Broader JH, Gunn IF, Alexander-Williams J</AU>
<TI>Evaluation of a bulk-forming evacuant in the management of haemorrhoids</TI>
<SO>British Journal of Surgery</SO>
<YR>1974</YR>
<VL>61</VL>
<NO>2</NO>
<PG>142-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foster-1979" NAME="Foster 1979" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foster GE, Bolwel JS, Wright J, Hardcastle JD</AU>
<TI>Controlled trial of bulk forming evacuants in the treatment of patients with haemorrhoids</TI>
<SO>GUT</SO>
<YR>1979</YR>
<VL>20</VL>
<NO>Suppl 2</NO>
<PG>A452</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hunt-1981" NAME="Hunt 1981" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hunt PS, Korman MG</AU>
<TI>Fybogel in haemorrhoid treatment</TI>
<SO>The Medical journal of Australia</SO>
<YR>1981</YR>
<VL>2</VL>
<NO>5</NO>
<PG>256-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-1988" NAME="Jensen 1988" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen SL, Harling H, Tange G, Shokouh-Amiri MH, Nielsen OV</AU>
<TI>Maintenance bran therapy for prevention of symptoms after rubber band ligation of third-degree haemorrhoids</TI>
<SO>Acta chirurgica Scandinavica</SO>
<YR>1988</YR>
<VL>154</VL>
<NO>5-6</NO>
<PG>395-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moesgaard-1982" NAME="Moesgaard 1982" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moesgaard F, Nielsen ML, Hansen JB, Knudsen JT</AU>
<TI>High-fiber diet reduces bleeding and pain in patients with haemorrhoids: a double-blind trial of Vi-Siblin</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>1982</YR>
<VL>25</VL>
<NO>5</NO>
<PG>454-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perez_x002d_Miranda-1996" NAME="Perez-Miranda 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Miranda M, Gomez-Cedenilla A, Leon-Colombo T, Pajares J, Mate-Jimenez J</AU>
<TI>Effect of fiber supplements on internal bleeding haemorrhoids</TI>
<SO>Hepatogastroenterology</SO>
<YR>1996</YR>
<VL>43</VL>
<NO>12</NO>
<PG>1504-507.</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Webster-1978" NAME="Webster 1978" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Webster DJ, Gough DC, Craven JL</AU>
<TI>The use of bulk evacuant in patients with haemorrhoids</TI>
<SO>British Journal of Surgery</SO>
<YR>1978</YR>
<VL>65</VL>
<NO>4</NO>
<PG>291-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Craven-1976" NAME="Craven 1976" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Craven JL</AU>
<TI>A controlled, double blind study of dietary fiber in patients with hemorrhoids</TI>
<SO>Symposium on dietary fiber. St James Hospital, Leeds</SO>
<YR>1976</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gorgul-1999" NAME="Gorgul 1999" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gorgul A. Mentes BB. Tascilar O. Ates Y. Kandilci U. Tatlicioglu E</AU>
<TI>The results and comparison of rubber band ligation and injection sclerotherapy supplemented by high-fibre diet in the treatment of second-degree internal hemorrihoids</TI>
<SO>Turkish Journal of Gastroenterology</SO>
<YR>1999</YR>
<VL>10</VL>
<NO>1</NO>
<PG>66-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hunt-1981a" NAME="Hunt 1981a" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hunt P, Stewardson A, Korman M</AU>
<TI>Double-blind trial of fybogel (isphaghula husk) in the treatment of haemorrhoids</TI>
<SO>Australian &amp; New Zealand Journal of Medicine</SO>
<YR>1981</YR>
<VL>11</VL>
<PG>221-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mat_x00e9_-1996" NAME="Maté 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maté J, Gómez A, Correa JA, León T, Pérez M, Pajares JM</AU>
<TI>Therapeutic Fiber and Bleeding Haemorrhoids</TI>
<SO>GUT</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>3</NO>
<PG>A140</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-05 11:10:20 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-05 11:10:20 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abcarian-1994" NAME="Abcarian 1994" TYPE="JOURNAL_ARTICLE">
<AU>Abcarian H, Alexander-Williams J, Christiansen J, Johanson J, Killingback M, Nelson RL, Ries-Neto J</AU>
<TI>Benign anorectal disease: definition, characterization and analysis of treatment</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1994</YR>
<VL>89</VL>
<NO>Suppl 8</NO>
<PG>S182-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abramowitz-2001" NAME="Abramowitz 2001" TYPE="JOURNAL_ARTICLE">
<AU>Abramowitz L, Godeberge P, Staumont G, Soudan D</AU>
<TI>Clinical practice guidelines for the treatment of hemorrhoid disease</TI>
<SO>Gastroenterologie clinique et biologique</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>6-7</NO>
<PG>674-702</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alderson-2004" MODIFIED="2008-08-05 11:10:20 +0200" MODIFIED_BY="[Empty name]" NAME="Alderson 2004" TYPE="COCHRANE_REVIEW">
<AU>Alderson P, Green S, Higgins JPT, editors</AU>
<TI>Cochrane Reviewers' Handbook 4.2.2 [updated March 2004].</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd.</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alonso-2002" NAME="Alonso 2002" TYPE="JOURNAL_ARTICLE">
<AU>Alonso P, Marzo M, Mascort JJ, Hervas A, Vinas L, Ferrus J, et al.</AU>
<TI>Clinical practice guidelines for the management of patients with rectal bleeding Gastroenterol Hepatol. 2002 Dec;25(10):605-32.</TI>
<SO>Gastroenterologia y hepatologia</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>10</NO>
<PG>605-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alonso_x002d_Coello-2003" NAME="Alonso-Coello 2003" TYPE="JOURNAL_ARTICLE">
<AU>Alonso-Coello P, Marzo M</AU>
<TI>Office evaluation and treatment of hemorrhoids. Office evaluation and treatment of hemorrhoids</TI>
<SO>The Journal of family practice</SO>
<YR>2003</YR>
<VL>52</VL>
<PG>366-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beck-1998" NAME="Beck 1998" TYPE="BOOK_SECTION">
<AU>Beck DE</AU>
<TI>Hemorrhoidal disease</TI>
<SO>Fundamentals of anorectal surgery</SO>
<YR>1998</YR>
<PG>237-53</PG>
<EN>2nd</EN>
<ED>Beck DE, Wexner SD</ED>
<PB>WB saunders edition</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bennett-1996" NAME="Bennett 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bennett WG, Cerda JJ</AU>
<TI>Dietary fiber: fact and fiction</TI>
<SO>Digestive Disease</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>43-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bleday-1992" NAME="Bleday 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bleday R, Pena JP, Rothenberger DA, Goldberg SM, Buls JG</AU>
<TI>Symptomatic hemorrhoids: current incidence and complications of operative therapy</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>1992</YR>
<VL>35</VL>
<PG>477-481</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brisinda-2000" NAME="Brisinda 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brisinda G</AU>
<TI>How to treat hemorrhoids</TI>
<SO>British Medical Journal</SO>
<YR>2000</YR>
<VL>321</VL>
<PG>582-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Devereaux-2004" NAME="Devereaux 2004" TYPE="JOURNAL_ARTICLE">
<AU>Devereaux PJ, Choi PT, El-Dika S, Bhandari M, Montori VM, Schunemann HJ, Garg AX, et al</AU>
<TI>An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2004</YR>
<VL>57</VL>
<NO>12</NO>
<PG>1232-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-2002" NAME="Dickersin 2002" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Manheimer E, Wieland S, Robinson KA, Lefebvre C, McDonald S</AU>
<TI>Development of the Cochrane Collaboration's CENTRAL Register of controlled clinical trials</TI>
<SO>Evaluation &amp; the health professions</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>1</NO>
<PG>38-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleiss-1973" NAME="Fleiss 1973" TYPE="JOURNAL_ARTICLE">
<AU>Fleiss JL, Cohen J</AU>
<TI>The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability</TI>
<SO>Educational and Psychological Measurement</SO>
<YR>1973</YR>
<VL>33</VL>
<PG>613-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fleiss-1993" NAME="Fleiss 1993" TYPE="JOURNAL_ARTICLE">
<AU>Fleiss JL</AU>
<TI>The statistical basis of meta-analysis</TI>
<SO>Statistical methods in medical research</SO>
<YR>1993</YR>
<VL>2</VL>
<PG>121-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johanson-1990" NAME="Johanson 1990" TYPE="JOURNAL_ARTICLE">
<AU>Johanson JF, Sonnenberg A</AU>
<TI>The prevalence of hemorrhoids and chronic constipation. An epidemiologic study</TI>
<SO>Gastroenterology</SO>
<YR>1990</YR>
<VL>98</VL>
<NO>2</NO>
<PG>380-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johanson-1992" NAME="Johanson 1992" TYPE="JOURNAL_ARTICLE">
<AU>Johanson JF, Rimm A</AU>
<TI>Optimal nonsurgical treatment of hemorrhhoids: a comparative analysis of infrared coagulation, rubber band ligation,and injection sclerotherapy</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1992</YR>
<VL>87</VL>
<PG>1600-606</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johanson-2002" NAME="Johanson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Johanson JF</AU>
<TI>Evidence-based approach to the treatment of hemorrhoidal disease</TI>
<SO>Evidence-Based Gastroenterology</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>1</NO>
<PG>26-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johanson-2002a" NAME="Johanson 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Johanson JF</AU>
<TI>Nonsurgical treatment of hemorrhoids</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2002</YR>
<VL>6</VL>
<NO>3</NO>
<PG>290-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2002" NAME="Jones 2002" TYPE="JOURNAL_ARTICLE">
<AU>Jones MP, Talley NJ, Nuyts G, Dubois D</AU>
<TI>Lack of objective evidence of efficacy of laxatives in chronic constipation</TI>
<SO>Digestive diseases and sciences</SO>
<YR>2002</YR>
<VL>47</VL>
<PG>2222-230</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" NAME="Juni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Juni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: assesing the quality of controlled clinical trials</TI>
<SO>British Medical Journal</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>42-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kenny-2001" NAME="Kenny 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kenny KA, Dkelly JM</AU>
<TI>Dietary fiber for constipation in older adults: a systematic review</TI>
<SO>Clinical Effectiveness in Nursing</SO>
<YR>2001</YR>
<VL>5</VL>
<PG>120-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Madoff-2004" NAME="Madoff 2004" TYPE="JOURNAL_ARTICLE">
<AU>Madoff RD, Fleshman JW; Clinical Practice Committee, American Gastroenterological Association</AU>
<TI>American Gastroenterological Association technical review on the diagnosis and treatment of hemorrhoids</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>5</NO>
<PG>1463-473</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perez_x002d_Miranda-1996" NAME="Perez-Miranda 1996" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Miranda M, Gomez-Cedenilla A, Leon-Colombo T, Pajares J, Mate-Jimenez J</AU>
<TI>Effect of fiber supplements on internal bleeding hemorrhoids</TI>
<SO>Hepatogastroenterology</SO>
<YR>1996</YR>
<VL>43</VL>
<PG>1504-507</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petticrew-2001" NAME="Petticrew 2001" TYPE="JOURNAL_ARTICLE">
<AU>Petticrew M, Rodgers M, Booth A</AU>
<TI>Effectivenes of laxatives in adults</TI>
<SO>Quality in Health care</SO>
<YR>2001</YR>
<VL>10</VL>
<PG>268-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spiller-1994" NAME="Spiller 1994" TYPE="JOURNAL_ARTICLE">
<AU>Spiller RC</AU>
<TI>Pharmacology of dietary fiber</TI>
<SO>Pharmacology &amp; therapeutics</SO>
<YR>1994</YR>
<VL>62</VL>
<PG>407-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tramonte-1997" NAME="Tramonte 1997" TYPE="JOURNAL_ARTICLE">
<AU>Tramonte SM, Brand MB, Mulrow CD, Amato MG, O'Keefe ME, Ramirez G</AU>
<TI>The treatment of chronic constipation in adults: a systematic review</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>15-24</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Broader-1974">
<CHAR_METHODS>
<P>Randomization schedule<BR/>Patients and observer blinded Treatment and placebo looked alike</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 outpatients with anal bleeding, prolapse or discomfort (I-III)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Stercullia vs. placebo (starch, &lt;20g/day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>-Bleeding, prolapse, discomfort<BR/>-Patient overall impression<BR/>-Adverse events<BR/>-Bowel habit</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Foster-1979">
<CHAR_METHODS>
<P>Parallel randomised controlled trial<BR/>Poorly described methodology. No details about validity issues</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>41 patients with hemorrhoids</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Isphagula husk vs. placebo<BR/>One month of treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>-Overall symptomatic improvement<BR/>-Anal and rectal pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only abstract available<BR/>Authors provided additional information<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hunt-1981">
<CHAR_METHODS>
<P>Parallel randomised controlled trial.<BR/>Random list prepared by throwing a coin*. Sealed envelopes*. <BR/>Everyone blinded except Head pharmacist who was aware of the list* (Described as double blind)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>28 patients with bleeding hemorrhoids (I-II)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Isphaghula husk vs. placebo Six weeks of treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>-Symptomatic improvement<BR/>-Proctoscopic improvement<BR/>-Bowel habit <BR/>-Overall symptomatic improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only abstract and a letter describing the main results available<BR/>Authors provided additional information.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jensen-1988">
<CHAR_METHODS>
<P>Parallel randomised controlled trial<BR/>Poorly described methodology<BR/>Evaluation of follow-up by independent observer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>92 patients with hemorrhoids grade III <BR/>Median age 47, 47% women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Unprocessed bran (20g/day) vs. no treatment<BR/>18 months of treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number or recurrences after RBL <BR/>Severity of symptoms<BR/>Laxatives intake<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Open study<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Moesgaard-1982">
<CHAR_METHODS>
<P>Parallel randomised controlled trial<BR/>Randomization schedule (table)*<BR/>Sealed envelopes*<BR/>Patients and investigators blinded*<BR/>Treatment and placebo looked alike*</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>52 outpatients with symptomatic hemorrhoids (I-II)<BR/>Mean age 54, 26% of women.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Psyllium seed dietary fiber (20g/day) vs. placebo<BR/>Six weeks of treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Bleeding<BR/>Pain at defecation<BR/>Pruritus and/or anal secretion<BR/>Prolapse<BR/>Overall assessment<BR/>Adverse events*</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding: industry provided medication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Perez_x002d_Miranda-1996">
<CHAR_METHODS>
<P>Parallel randomised controlled trial<BR/>Computer generated list*<BR/>Endoscopist and analyst blinded*. <BR/>Health providers and patients not blinded (Patients not aware of therapeutic effect*)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>50 outpatients with internal bleeding hemorrhoids (I-IV) referred to colorectal outpatient clinic<BR/>Mean age 48, 42% women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Plantago ovata (11.6 g/day vs. placebo (vitamin B preparation)<BR/>40 days of treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>-Average number of bleeding episodes<BR/>-Number of congested hemorrhoidal cushions<BR/>-Hemorrhoids bleeding on contact <BR/>-Degree of prolapse<BR/>-Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Undertaken without funding*</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Webster-1978">
<CHAR_METHODS>
<P>Cross-over randomised controlled trial<BR/>Randomization centrally and placed in sequentially numbered envelopes by sponsor*<BR/>Sealed envelopes (opened when patient agreed to enter study)*<BR/>Surgeons and patients blinded*</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>67 outpatients with symptomatic hemorrhoids referred to an outpatient surgery clinic (I-III)<BR/>Age 23-71, 37% women</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Isphaghula husk (7g/day) vs. placebo<BR/>6 weeks of treatment (Assessment at six and 12 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>-Pruritus, prolapse, bleeding and overall symptoms<BR/>-Days of laxatives used<BR/>-Consistency of faeces<BR/>-Frequency of defaecation<BR/>-Proctoscopic evaluation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Cross-over with 2 periods of 6 weeks of treatment<BR/>Funding: industry provided medication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>* Information provided by authors</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Craven-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract from a symposium, and apparently never published as a full article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gorgul-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hunt-1981a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract of a full text article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mat_x00e9_-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract of a full text article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Broader-1974">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Foster-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hunt-1981">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jensen-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Moesgaard-1982">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Perez_x002d_Miranda-1996">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Webster-1978">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2008-08-05 11:14:36 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2008-08-05 11:14:36 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trialflow.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>